Meta-Analysis
Copyright ©The Author(s) 2024.
World J Clin Cases. Jul 26, 2024; 12(21): 4691-4702
Published online Jul 26, 2024. doi: 10.12998/wjcc.v12.i21.4691
Table 2 Characteristics of the included studies
Ref.
Study design
Intervention
Outcomes
FMT
Control mode
CR (n/total)
Adverse events
Follow up (weeks)
Reference standard of CR
pre-FMT therapy
Delivery route
FMT
Control
Moayyedi et al[7], 2015Double-blind, RCTNREnemaWater enema9/362/3557Mayo score ≤ 2, endoscopic Mayo score of 0
Rossen et al[8], 2015Double-blind, RCTBowel lavageVia naso-duodenal tubeAFM7/175/20412SCCAI scores ≤ 2, Mayo endoscopic score decrease ≥ 1
Paramsothy et al[15], 2016Double-blind, RCTNRColonoscopic infusionNR18/418/4038Mayo score ≤ 2 points with subscores ≤ 1
Costello et al[16], 2017Double-blind, RCTNRColonoscopic infusionAFM19/3517/3458Mayo score of ≤ 2 with an endoscopic Mayo score of ≤ 1
Crothers et al[10], 2018Double-blind, RCT7 days of antibioticsColonoscopic infusion and daily FMTcSham FMT2/70/8NR12> 3 point reduction in Mayo score
Midha et al[14], 2018Double-blind, RCTNRNRNR12/144/14048Mayo score = 1
Zhang et al[11], 2019RCTSulfapyridine 0.75 g, qidEnemaSulfapyridine 0.75 g, qid48/5035/509NRNR
Kedia et al[13], 2022Open-labeled RCTFMT + UC-SAIDColonoscopic infusionSMT21/3510/31NR8Decline in SCCAI > 3
Tkach et al[12], 2022RCTMesalazine 1 g, tidColonoscopic infusionSMT21/2619/2788Partial Mayo score ≤ 2